US pharmaceutical company Eli Lilly and Company reported its results today, which beat expectations and $LLY shares are up more than 15% in response. Fundamentals are quite solid and the stock is up over 40% for the year, which I like and since I see potential in healthcare and I like pharmaceutical and medical companies, I like this company even more :D. The stock may be up,... Read more
In Patria's coverage, there's one more link "Unexpectedly good quarterly numbers came together today with results from Novo Nordisk's clinical trial for rival Wegova. As Mounjaro is based on a similar principle (GLP-1/GIP analogue), its indication is expected to be extended to cardiovascular disease in the future as well."
In an intermediate clinical trial, the highest dose of Eli Lilly's experimental orforglipron $LLY pill led to a 14.7% weight loss in obese or overweight people after 36 weeks, setting a new milestone in the race to develop effective anti-obesity pills.
I think it will be appreciated by far more people than just the Americans... imagine what results you could achieve if you ate right, exercised + supported it with similar pills? What normally takes you a year you could have in a few weeks... :)
Charlie Munger and his view of healthcare in the US.
Charlie, a friend, partner of Warren, has recently been vocal about his concerns about US healthcare, literally stating that it is a system that prolongs death to make more money and comparing patients to African carcasses. 🤔
A bit off topic from the classic stocks we cover here, but if we look at the most capitalised US companies, the top ranks are also companies like $UNH$LLY$PG etc. Which according to the chart appear to be endlessly growing companies, which I admit I don't know as much about as the companies we all know like Microsoft, Apple... Do you own any of these companies that don't get... Read more
In Patria's coverage, there's one more link "Unexpectedly good quarterly numbers came together today with results from Novo Nordisk's clinical trial for rival Wegova. As Mounjaro is based on a similar principle (GLP-1/GIP analogue), its indication is expected to be extended to cardiovascular disease in the future as well."